Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.

Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group..

BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3.

2.

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team..

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.

3.

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.

Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group..

PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015. Erratum in: PLoS One. 2016;11(6):e0157094.

4.

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.

Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK; DART Virology Group.; DART Trial Team..

AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10.

5.

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.

Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndembi N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Teams..

J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14.

6.

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.

Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team..

PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014.

7.

High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.

Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Team..

Clin Infect Dis. 2014 Apr;58(7):1023-6. doi: 10.1093/cid/cit933. Epub 2013 Dec 18.

8.

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.

Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugyenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team..

PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21.

Supplemental Content

Loading ...
Support Center